Science & Technology
Bio Sidus S.A.
Innovative Biotechnology Enterprise Engaged in Cutting-Edge Research Bio Sidus S.A., founded in 1983, has become a leading developer and supplier of world-class biopharmaceutical products to 30 countries throughout Latin America, Asia, the Middle East, Africa and Eastern Europe. It achieves annual turnover of around US$40 million (€28.7 million) and is a global leader in sales of biosimilar recombinant human erythropoietin (EPO) and other cutting-edge biogeneric products. The fast-growing enterprise, which already operates according to the highest international standards, plans to enter the European, North American and Australian markets in the next few years, and Marcelo Argüelles, Bio Sidus’s President, is currently looking for partners to help the company achieve its goals in these markets. Bio Sidus excels at delivering high quality biopharmaceuticals at affordable prices.
History of innovation
The company also counts on a robust pipeline of product candidates in different stages of development.
First EPO developed in Latin America Bio Sidus launched EPO in 1990, the first recombinant human protein fully developed and manufactured in Latin America. To date, Bio Sidus has launched seven recombinant proteins currently distributed in Argentina and abroad. Continuing to innovate, Bio Sidus now has more than 10 biomolecules in its pipeline, and continues to conduct groundbreaking research in transgenic animals and gene therapy.
High-tech facilities to meet international standards Bio Sidus has two manufacturing sites in the city: the 6,200 sq m Almagro plant, which focuses on manufacturing active
Bio Sidus has been expanding its activities over the years. In 1980, the original pharmaceuticals company, Sidus, branched out into cutting-edge biotechnology activities, including cell cultures, genetic engineering and protein purification. Since the launch of our first product in 1990, we have manufactured and sold more than 60 million drug product units in emerging markets, with more than 75% of our revenues, for fiscal year 2008, derived from sales outside Argentina, and approximately 40% from sales outside Latin America. Bio Sidus’s proven expertise in Biotech manufacturing methods has resulted in a wide range of biopharmaceuticals, which include Interferon alfa 2a, Interferon alfa 2b, Filgrastim and Somatropin, all produced through bacterial fermentation; and Epoetin, Lenograstim and Interferon Beta 1a, produced through mass cell culture.
31